Related references
Note: Only part of the references are listed.Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
Elizabeth O. Hexner et al.
BLOOD (2008)
JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling
Sven Schwernmers et al.
EXPERIMENTAL HEMATOLOGY (2007)
Hematopoietic cytokine receptor signaling
S. J. Baker et al.
ONCOGENE (2007)
JAK2 V617F: implications for thrombosis in myeloproliferative diseases
Elizabeth O. Hexner
CURRENT OPINION IN HEMATOLOGY (2007)
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
A. Pardanani et al.
LEUKEMIA (2007)
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis
Stefan O. Ciurea et al.
BLOOD (2007)
Structural analysis identifies imidazo[1,2-b]Pyridazines as PIM kinase inhibitors with In vitro antileukemic activity
Vanda Pogacic et al.
CANCER RESEARCH (2007)
Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation
Luciana Teofili et al.
BLOOD (2007)
Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis
Boryana Konstantinova Popivanova et al.
CANCER SCIENCE (2007)
Mechanisms of disease: The myeloproliferative disorders
Peter J. Campbell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The JAK-STAT pathway: A therapeutic target in hematological malignancies
A. Ferrajoli et al.
CURRENT CANCER DRUG TARGETS (2006)
Oncogenic mechanisms in myeloproliferative disorders
F. Delhommeau et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells
Loic Garcon et al.
BLOOD (2006)
Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes
Denise K. Walters et al.
LEUKEMIA RESEARCH (2006)
Constitutively activated FLT3 phosphorylates BAD partially through Pim-1
Kyu-Tae Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates Bad to block Bad-mediated apoptosis in human pancreatic cancer cell lines
Ying-Yi Li et al.
CANCER RESEARCH (2006)
Activated Jak2 with the V617F point mutation promotes G1/S phase transition
Christoph Walz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL
M Adam et al.
CANCER RESEARCH (2006)
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders
H Quentmeier et al.
LEUKEMIA (2006)
Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL
A Macdonald et al.
BMC CELL BIOLOGY (2006)
The survival kinases Akt and Pim as potential pharmacological targets
R Amaravadi et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
The serine/threonine kinase pim-1
M Bachmann et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2005)
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival
KT Kim et al.
BLOOD (2005)
The stats of cancer - New molecular targets come of age
H Yu et al.
NATURE REVIEWS CANCER (2004)
Pim-1 kinase promotes inactivation of the pro-apoptotic bad protein by phosphorylating it on the Ser112 gatekeeper site
TLT Aho et al.
FEBS LETTERS (2004)
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells
E Tenedini et al.
BLOOD (2004)
The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death
B Yan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Keeping killers on a tight leash: transcriptional and posttranslational control of the pro-apoptotic activity of BH3-only proteins
H Puthalakath et al.
CELL DEATH AND DIFFERENTIATION (2002)
Signaling through the JAK/STAT pathway, recent advances and future challenges
T Kisseleva et al.
GENE (2002)
Antiapoptotic protein Bcl-xL is up-regulated during megakaryocytic differentiation of CD34+ progenitors but is absent from senescent megakaryocytes
C Sanz et al.
EXPERIMENTAL HEMATOLOGY (2001)
Janus kinases: components of multiple signaling pathways
SG Rane et al.
ONCOGENE (2000)
Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles
K Uozumi et al.
LEUKEMIA (2000)
Share Paper
